{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:36:26Z","timestamp":1790638586763,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with a high mortality rate. While up to 20% of PDAC patients harbor mutations in genes involved in homologous recombination (HR) repair, only 5% of germline\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutation carriers have an approved treatment option with the PARP inhibitor (PARPi) olaparib. Characterizing HR\u2010deficient (HRD) genotypes beyond g\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      that are susceptible to PARPi has potential to substantially broaden the eligible patient population, and defining the optimal inhibitor may further optimize treatment strategies to advance personalized medicine in PDAC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Our previous preclinical work showed synthetic lethality of a multi\u2010pronged DNA damage repair interference strategy using the PARPi olaparib, ATR inhibitor VE\u2010822, and DNA\u2010PK inhibitor CC\u2010115 (termed PAD) in ATM deficiency. In the present study, we challenged the role of olaparib in our PAD combination and assessed the regimen's efficacy across various HRD genotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We assessed a spectrum of DNA damage repair\u2010interfering drugs to identify the most potent inhibitor in HRD. Using\n                      <jats:italic>ATM<\/jats:italic>\n                      ,\n                      <jats:italic>BRCA1<\/jats:italic>\n                      ,\n                      <jats:italic>BRCA2<\/jats:italic>\n                      and\n                      <jats:italic>PALB2<\/jats:italic>\n                      \u2010defective versus HR\u2010proficient murine PDAC cells, we systematically investigated the feasibility of expanding an optimized PAD regimen within defined HRD genotypes in vitro and in vivo. The regimen's efficacy was validated in PDAC patient\u2010derived organoids with and without deleterious class IV\/V alterations in HRD genes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and Conclusion<\/jats:title>\n                    <jats:p>\n                      Here, we demonstrate a remarkable potency of the PARPi talazoparib in HRD PDAC. Substituting olaparib, currently the only approved inhibitor in PDAC, with talazoparib in our PAD regimen enhanced its efficacy while maintaining comparable tolerability in vivo. Importantly, we show that PAD is an effective therapeutic regimen that can be extended to the most prevalent HR\u2010defective genotypes in PDAC including\n                      <jats:italic>ATM<\/jats:italic>\n                      ,\n                      <jats:italic>BRCA1<\/jats:italic>\n                      ,\n                      <jats:italic>BRCA2<\/jats:italic>\n                      and\n                      <jats:italic>PALB2<\/jats:italic>\n                      in a preclinical setting. Collectively, these data provide a strong rationale to implement the refined regimen, talazoparib\u2010based PAD, as a therapeutic concept tailored for HRD PDAC patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ueg2.12773","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:51:41Z","timestamp":1755517901000},"page":"1328-1342","source":"Crossref","is-referenced-by-count":4,"title":["Homologous Repair\u2010Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9573-0333","authenticated-orcid":false,"given":"Alica K.","family":"Beutel","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I University Hospital Ulm  Ulm Germany"},{"name":"Department of Molecular Biology and Biochemistry University of California Irvine  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-3114","authenticated-orcid":false,"given":"Christopher J.","family":"Halbrook","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Biochemistry University of California Irvine  Irvine California USA"},{"name":"Chao Family Comprehensive Cancer Center University of California Irvine  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-8958","authenticated-orcid":false,"given":"Menar","family":"Ekizce","sequence":"additional","affiliation":[{"name":"Institute of Molecular Oncology and Stem Cell Biology Ulm University Hospital  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3673-5995","authenticated-orcid":false,"given":"Jessica","family":"Lindenmayer","sequence":"additional","affiliation":[{"name":"Core Facility Organoids Ulm University  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-6292","authenticated-orcid":false,"given":"Elodie","family":"Roger","sequence":"additional","affiliation":[{"name":"Institute of Molecular Oncology and Stem Cell Biology Ulm University Hospital  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina E.","family":"Calderon","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Biochemistry University of California Irvine  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3259-0810","authenticated-orcid":false,"given":"Thomas","family":"Seufferlein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Hospital Ulm  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0592-5232","authenticated-orcid":false,"given":"Alexander","family":"Kleger","sequence":"additional","affiliation":[{"name":"Institute of Molecular Oncology and Stem Cell Biology Ulm University Hospital  Ulm Germany"},{"name":"Core Facility Organoids Ulm University  Ulm Germany"},{"name":"Division of Interdisciplinary Pancreatology Department of Internal Medicine I Ulm University Hospital  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0522-9800","authenticated-orcid":false,"given":"Johann","family":"Gout","sequence":"additional","affiliation":[{"name":"Institute of Molecular Oncology and Stem Cell Biology Ulm University Hospital  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0484-0974","authenticated-orcid":false,"given":"Lukas","family":"Perkhofer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Hospital Ulm  Ulm Germany"},{"name":"Institute of Molecular Oncology and Stem Cell Biology Ulm University Hospital  Ulm Germany"},{"name":"Division of Interdisciplinary Pancreatology Department of Internal Medicine I Ulm University Hospital  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.07.007"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102019\u2010319984"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1097\u20102765(01)00174\u20105"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.05.022"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03238"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14169"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/po.19.00115"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201020\u20100418"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201007\u20100601"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1903387"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01604"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00003"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201012\u20102753"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.mct\u201013\u20100803"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201022\u20100412"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.290957.116"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010019\u201012836\u20109"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102019\u2010319970"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541\u20107786.mcr\u201015\u20100191\u2010t"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010020\u201000956\u20105"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092110"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010021\u201026059\u20104"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201018\u20100349"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2020.1762398"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050640620905183"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388\u2010020\u20101328\u2010y"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20342"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0017"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.7401"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201013\u20101391"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541\u20107786.mcr\u201018\u20100138"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018\u2010022\u201000439\u20101"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.11.004"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02931"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1802905"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416\u2010020\u201001151\u20106"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.024"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.3018"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201017\u20100634"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226714"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20101\u20100716\u20102513\u20102_5"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010017\u201017204\u20105"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.12.021"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2020.100192"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112539"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135544"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ueg2.12773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:55:53Z","timestamp":1761137753000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ueg2.12773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/ueg2.12773"],"URL":"https:\/\/doi.org\/10.1002\/ueg2.12773","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}